In this webinar, you will learn how technology can influence rare disease clinical study design, increase the speed of research and thereby reduce the overall research burden. Our experts will introduce and educate clinical teams on how innovative technology can impact the future of rare disease clinical development.

Studies and clinical trials in the rare disease space are complex and, have novel designs or new endpoints. They are often unique in design, cost and revenue structures. When you factor in how inherently different each patient’s disease state, age and geographic location, finding an experienced research site can be difficult. While these studies may present some research challenges, structuring them with the right technology can get clinical teams over the study design hurdles and help improve patient recruitment and retention by decreasing trial burden.

Discussion topics include:

Decreasing trial burden on patients via patented clinical care technology
Increasing study retention using mobile and connected devices
Speeding up rare disease research through real-time, device-based data collection

Keywords:

Speakers

Scott Schliebner, MPH, Senior Vice President, Center for Rare Diseases

Scott Schliebner, MPH, Senior Vice President, Center for Rare Diseases, is a clinical strategist with a 20+ year background in clinical drug development, focused on rare diseases and orphan drugs. Mr. Schliebner has served in leadership roles across the biotech, non-profit, and CRO settings and has developed close working relationships with rare disease research consortia, patient advocacy organizations, study research groups, and key opinion leaders. He is regularly asked to speak on patient-focused approaches to drug development, leveraging real word evidence, and innovative strategies to reduce the burden of participating in clinical trials. He holds an MPH from the University of Utah School of Medicine, and completed a Graduate Research Fellowship at the National Institutes of Health.

Message Presenter

David Turner, MS, CISA, CEO/Founder, Parallel6, a PRA Health Sciences Company

With 20+ years in industry, Mr. Turner’s primary focus has been executive leadership, entrepreneurship, product innovation, packaging, pricing, and overall market direction for technology related companies. He holds several patents in the Clinical Research and Healthcare space and most recently sold Parallel6 Inc to PRA Health Sciences. He is the CEO and founder of Parallel6, a PRA Health Sciences Company, and the inventor of Clinical6 an mClinical platform that serves the pharma and healthcare sectors.

Mr. Turner has a bachelor’s degree in economics and a master’s in information systems from Louisiana State University.

Message Presenter

Who Should Attend?

Those interested in patient-centric approaches to facilitate clinical research
C-level and senior professionals from biotechnology companies involved in the research and development of orphan drugs
Procurement and outsourcing professionals with a focus on rare and orphan disease
Senior professionals from biopharmaceutical companies working on rare disease compounds

Relevant job functions include:

Research & Development
Clinical Affairs
Clinical Research
Clinical Pharmacology
Clinical Operations
Medical Affairs
Project Management

What You Will Learn

How patented clinical care technology can decrease the burden of the trial on the patient
How mobile and connected devices can help to increase patient retention
How to accelerate rare disease research through real-time, device-based data collection

Xtalks Partner

PRA Health Sciences

PRA Health Sciences (PRA) provides biopharmaceutical companies, drug developers, and the US government with innovative solutions that advance drug discovery and help improve patients’ lives. Established in 1982, we have worked on 100+ marketed drugs across several therapeutic areas and have participated in the pivotal or supportive trials that led to Food and Drug Administration (FDA) and/or international regulatory approval of 75+ such drugs, 18 of which treat rare diseases.

With 15,000+ employees in 70+ offices, we provide coverage for 85+ countries and deliver comprehensive clinical development services across all phases. Our expertise in full-service clinical development and the pioneering Embedded Solutions™ model enables us to meet the demands of a diverse marketplace.